These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
325 related items for PubMed ID: 16910420
1. [Strontium ranelate--new paradigm in the treatment of postmenopausal osteoporosis]. Korsić M, Giljević Z, Kastelan D. Lijec Vjesn; 2006; 128(5-6):180-2. PubMed ID: 16910420 [Abstract] [Full Text] [Related]
3. [The efficacy of strontium ranelate (Osseor) on fractures in osteoporosis]. Novak S. Reumatizam; 2008 Jun; 55(2):75-7. PubMed ID: 19024282 [Abstract] [Full Text] [Related]
4. Strontium ranelate: an increased bone quality leading to vertebral antifracture efficacy at all stages. Ortolani S, Vai S. Bone; 2006 Feb; 38(2 Suppl 1):19-22. PubMed ID: 16455319 [Abstract] [Full Text] [Related]
5. Protelos: nonvertebral and hip antifracture efficacy in postmenopausal osteoporosis. Adami S. Bone; 2006 Feb; 38(2 Suppl 1):23-7. PubMed ID: 16434247 [Abstract] [Full Text] [Related]
6. Effects of long-term strontium ranelate treatment on the risk of nonvertebral and vertebral fractures in postmenopausal osteoporosis: Results of a five-year, randomized, placebo-controlled trial. Reginster JY, Felsenberg D, Boonen S, Diez-Perez A, Rizzoli R, Brandi ML, Spector TD, Brixen K, Goemaere S, Cormier C, Balogh A, Delmas PD, Meunier PJ. Arthritis Rheum; 2008 Jun; 58(6):1687-95. PubMed ID: 18512789 [Abstract] [Full Text] [Related]
7. Addressing and meeting the needs of osteoporotic patients with strontium ranelate: a review. Boonen S. Curr Opin Rheumatol; 2006 Jun; 18 Suppl 1():S21-7. PubMed ID: 16735842 [Abstract] [Full Text] [Related]
11. Long-term treatment of postmenopausal osteoporosis with strontium ranelate: results at 8 years. Reginster JY, Bruyère O, Sawicki A, Roces-Varela A, Fardellone P, Roberts A, Devogelaer JP. Bone; 2009 Dec; 45(6):1059-64. PubMed ID: 19679207 [Abstract] [Full Text] [Related]
12. Cost-effectiveness of strontium ranelate versus risedronate in the treatment of postmenopausal osteoporotic women aged over 75 years. Hiligsmann M, Bruyère O, Reginster JY. Bone; 2010 Feb; 46(2):440-6. PubMed ID: 19716940 [Abstract] [Full Text] [Related]
14. Strontium ranelate: a physiological approach for optimizing bone formation and resorption. Marie PJ. Bone; 2006 Feb; 38(2 Suppl 1):S10-4. PubMed ID: 16439191 [Abstract] [Full Text] [Related]
15. The effects of strontium ranelate in Asian women with postmenopausal osteoporosis. Hwang JS, Chen JF, Yang TS, Wu DJ, Tsai KS, Ho C, Wu CH, Su SL, Wang CJ, Tu ST. Calcif Tissue Int; 2008 Nov; 83(5):308-14. PubMed ID: 18843436 [Abstract] [Full Text] [Related]
16. Generalized cutaneous drug eruption due to strontium ranelate. Boada A, Carrascosa JM, Leal L, Ferrándiz C. J Eur Acad Dermatol Venereol; 2009 Mar; 23(3):321-2. PubMed ID: 18624862 [No Abstract] [Full Text] [Related]
17. Strontium as therapy for osteoporosis. Marie PJ. Curr Opin Pharmacol; 2005 Dec; 5(6):633-6. PubMed ID: 16183330 [Abstract] [Full Text] [Related]
18. Strontium ranelate: a dual mode of action rebalancing bone turnover in favour of bone formation. Marie PJ. Curr Opin Rheumatol; 2006 Jun; 18 Suppl 1():S11-5. PubMed ID: 16735840 [Abstract] [Full Text] [Related]